| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Elosulfase alfa |
| Brand | Vimzim® |
| Indication | For the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages. |
| Assessment Process | |
| Rapid review commissioned | 30/03/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 04/04/2016 |
| NCPE assessment completed | 08/12/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended. The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated. |
The HSE has approved reimbursement following confidential price negotiations: May 2018
